Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
NEW YORK, NY / ACCESSWIRE / May 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVi
The positive opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy and safety of risankizumab in adults with moderately to severely active ulce
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
12:00pm, Thursday, 30'th May 2024
NEW YORK, NY / ACCESSWIRE / May 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVi
AbbVie: Turnaround Lurking After The Correction Pain (Upgrade)
11:30am, Thursday, 30'th May 2024
AbbVie stock has fallen into a correction, declining nearly 16% from its March 2024 highs. Despite the pullback, AbbVie remains a highly profitable company with a strong portfolio and robust long-term
3 Dividend Stocks to Double Up on Right Now
05:45am, Thursday, 30'th May 2024
AbbVie is a Dividend King in good shape to deliver solid growth through the rest of the decade. Chevron should reward investors with growing dividends and the "invisible dividends" of stock buybacks.
Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered
05:10pm, Wednesday, 29'th May 2024
AbbVie, a key player in my dividend growth portfolio, boasts a strong 4% yield and a consistent record of annual hikes. Its robust product lineup and innovative pipeline promise growth. Despite losing
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
01:04pm, Wednesday, 29'th May 2024
NEW YORK--(BUSINESS WIRE)---- $ABBV #classaction--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
10:05am, Wednesday, 29'th May 2024
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform
08:00am, Tuesday, 28'th May 2024
New safety and efficacy data in heavily pre-treated patients with metastatic colorectal cancer (CRC), from a Phase 1 study of ABBV-400, a next-generation, potential best-in-class c-Met directed ADC. D
7 Biotech Stocks to Put on Your Breakthrough Radar
12:32pm, Monday, 27'th May 2024
For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let's get some of the bad stuff out of the way fir
Forget Nvidia, Buy This Magnificent Healthcare Stock Instead
08:10am, Sunday, 26'th May 2024
Nvidia's high valuation could make the stock vulnerable to a sell-off if the company fall short of expectations. AbbVie is a top healthcare company with underrated growth prospects.
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
05:46am, Saturday, 25'th May 2024
AbbVie offers a high dividend yield and a great track record of dividend increases. Lowe's Companies is a Dividend King poised to benefit from the aging of U.S. homes.
Sell Alert: 2 Dividend Stocks To Sell In May And Go Away
11:03am, Friday, 24'th May 2024
The "Sell in May and go away" adage suggests selling stocks in May and returning in November, but historical data shows that June and July have been strong months. September is consistently the worst
High Yields And Low Multiples - 3 Of My Favorite Dividend Stocks To Buy Right Now
07:30am, Friday, 24'th May 2024
JPMorgan CEO Jamie Dimon expressed concern about inflation and predicts higher interest rates for longer than expected. He highlighted secular drivers such as the energy transition, geopolitical issue
AbbVie Completes Acquisition of Landos Biopharma
04:05pm, Thursday, 23'rd May 2024
- Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD) NORTH CHI
